Thomas King

Alexza Pharmaceuticals, Inc. is a pharmaceutical company. It focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are AZ-002 and AZ-007. The company was founded by Alejandro C. Zaffaroni in 2000 and is headquartered in Mountain View, CA.

Symphony Allegro, Inc. manufactures biopharmaceutical drugs. It develops clinical trials for the treatment of schizophrenia, bipolar, migraine, and panic attack disorders. The company was founded in 2006 and is headquartered in Rockville, MD.

Cognetix, Inc. discovered and developed drugs. Its products were used for the treatment of epilepsy, local anesthesia, heart disease, stroke, neuromuscular back pain, multiple sclerosis, and spinal cord injury. The company was founded in 1996 by Dennis B. Farrar, Baldomero M. Olivera and J. Michael McIntosh and was headquartered in Salt Lake City, UT

Anesta Corp. developed new pharmaceutical products for oral transmucosal drug administration. The company was founded by Theodore H. Stanley in 1985 and was headquartered in Salt Lake City, UT.

Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA.

Orphan Medical, Inc. develops and markets pharmaceutical and health care products. The company was founded in 1993 and is located in Minnetonka, MN.

Faraday Pharmaceuticals, Inc. engages in the research and development of elemental reducing agents (ERAs). Its therapeutic agents have potential applications for treatment of critical care illnesses. The company was founded by Mark B. Roth and Christopher Toombs in 2014 and is headquartered in Seattle, WA.